Main clinicohematologic characteristics at diagnosis in 300 patients with low-risk ET
| . | Observation (n = 102) . | Antiplatelet therapy (n = 198) . |
|---|---|---|
| Median age, y (range) | 35 (5-59) | 41 (13-59) |
| Male/female, n/n | 36/66 | 65/133 |
| Cardiovascular risk factors | ||
| Smoking, n (%) | 28 (27) | 47 (24) |
| Hypertension, n (%) | 8 (8) | 29 (15) |
| Hypercholesterolemia, n (%) | 12 (12) | 45 (23) |
| Diabetes, n (%) | 4 (4) | 7 (4) |
| Median hemoglobin level, g/L (range) | 140 (110-170) | 141 (115-171) |
| Median WBC count, ×109/L (range) | 8.6 (4.1-18.8) | 9.1 (3.9-16.5) |
| Median platelet count, ×109/L (range) | 817 (498-2328) | 767 (457-2400) |
| JAK2 V617F mutation, n (%)* | 30 (40) | 82 (48) |
| . | Observation (n = 102) . | Antiplatelet therapy (n = 198) . |
|---|---|---|
| Median age, y (range) | 35 (5-59) | 41 (13-59) |
| Male/female, n/n | 36/66 | 65/133 |
| Cardiovascular risk factors | ||
| Smoking, n (%) | 28 (27) | 47 (24) |
| Hypertension, n (%) | 8 (8) | 29 (15) |
| Hypercholesterolemia, n (%) | 12 (12) | 45 (23) |
| Diabetes, n (%) | 4 (4) | 7 (4) |
| Median hemoglobin level, g/L (range) | 140 (110-170) | 141 (115-171) |
| Median WBC count, ×109/L (range) | 8.6 (4.1-18.8) | 9.1 (3.9-16.5) |
| Median platelet count, ×109/L (range) | 817 (498-2328) | 767 (457-2400) |
| JAK2 V617F mutation, n (%)* | 30 (40) | 82 (48) |
ET indicates essential thrombocythemia; and WBC, white blood cell.
Of 74 and 169 assessable patients for observation and antiplatelet groups, respectively.